This comparison examines Bausch + Lomb Corporation (BLCO) and IDEXX Laboratories, Inc. (IDXX), two healthcare-focused companies with distinct business models and market exposures. BLCO serves the eye health sector through vision care, surgical instruments, and pharmaceuticals, while IDXX leads in veterinary diagnostics and related pet healthcare innovations. Traders and investors seeking to understand relative performance, sector-specific drivers, and recent sentiment shifts between consumer-oriented medical devices and animal health diagnostics may find this analysis relevant. The review draws on observable market data and developments from recent weeks to highlight contrasts in business context, momentum, and positioning without forward-looking speculation.
Bausch + Lomb Corporation (BLCO) develops, manufactures, and markets a range of eye health products, including contact lenses, intraocular lenses, surgical equipment, and prescription pharmaceuticals. In recent market activity, the company reported second-quarter 2026 results on July 29, delivering revenue of approximately $1.39 billion to $1.4 billion, reflecting about 9% year-over-year growth and beating consensus estimates. Management raised full-year 2026 guidance based on broad-based performance across segments and positive cash flow trends. Stock behavior in recent weeks has reflected measured responses to these results, with shares trading around $16.91 as of July 31. Sentiment has been influenced by consistent execution in vision care resilience and surgical demand, contributing to stable positioning amid broader healthcare sector movements.
IDEXX Laboratories, Inc. (IDXX) provides diagnostic products and services primarily for companion animals, livestock, and poultry, with a strong emphasis on recurring revenue from test kits and software solutions in veterinary practices. Recent market activity includes the release of its 2025 Corporate Responsibility Report on July 28 and continued anticipation ahead of second-quarter 2026 financial results scheduled for August 4. The company previously reported robust first-quarter 2026 revenue growth of 14% as reported (11% organic), supported by companion animal diagnostics recurring revenue and raised full-year guidance. Shares have traded near $559 as of July 31, with year-to-date performance showing variability relative to major indices. Sentiment in recent weeks has centered on sustained demand in pet healthcare and operational execution ahead of the upcoming earnings release.
Tickeron’s Trending AI Robots page showcases a curated selection of AI-powered trading bots designed for various market conditions. Tickeron offers hundreds of AI Trading Bots that can trade thousands of different tickers across equities, options, and other instruments. Only the strongest performers suited to prevailing trends earn placement in the Trending AI Robots section. Available bots exhibit a wide range of statistics, including win rates often between 55% and 75%, profit factors above 1.5 in many cases, and varying drawdown levels depending on strategy. These systems employ diverse trading styles, timeframes from intraday to multi-week, and specialized ticker sets. All AI trading bots feature unique performance metrics, risk parameters, and backtested results. Review the full selection on the Trending AI Robots page for additional details.
BLCO and IDXX operate in adjacent yet differentiated healthcare segments. BLCO’s model centers on eye health with exposure to elective procedures and consumer products, while IDXX derives significant recurring revenue from veterinary diagnostics and software. Recent momentum shows BLCO benefiting from Q2 earnings delivery and guidance increases, contrasting with IDXX’s focus on upcoming quarterly results following prior growth. Risk factors include regulatory and reimbursement dynamics for both, though BLCO faces additional currency and competitive pressures in vision care, whereas IDXX contends with pet ownership trends and diagnostic adoption rates. Sector exposure places BLCO in broader medical devices and IDXX in specialized animal health. Market sentiment reflects BLCO’s recent operational highlights against IDXX’s established growth profile and earnings catalyst timing, creating distinct trade-offs for investors evaluating stability versus recurring-revenue characteristics.
Based on observable factors such as recent trend consistency around earnings delivery, guidance revisions, and relative positioning, Tickeron’s AI would currently assign a probabilistic preference toward BLCO. The stock’s broad-based Q2 performance and raised outlook provide measurable support for near-term stability compared with IDXX’s positioning ahead of its August earnings release. This assessment remains probabilistic and tied to verifiable data points rather than definitive projections.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BLCO’s FA Score shows that 1 FA rating(s) are green whileIDXX’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BLCO’s TA Score shows that 5 TA indicator(s) are bullish while IDXX’s TA Score has 5 bullish TA indicator(s).
BLCO (@Pharmaceuticals: Other) experienced а +4.58% price change this week, while IDXX (@Medical Specialties) price change was +2.71% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +5.03%. For the same industry, the average monthly price growth was +0.09%, and the average quarterly price growth was -1.71%.
The average weekly price growth across all stocks in the @Medical Specialties industry was +0.40%. For the same industry, the average monthly price growth was -3.39%, and the average quarterly price growth was +6.80%.
BLCO is expected to report earnings on Nov 04, 2026.
IDXX is expected to report earnings on Aug 04, 2026.
Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
@Medical Specialties (+0.40% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| BLCO | IDXX | BLCO / IDXX | |
| Capitalization | 6.03B | 44.1B | 14% |
| EBITDA | 735M | 1.56B | 47% |
| Gain YTD | -0.995 | -17.362 | 6% |
| P/E Ratio | N/A | 41.14 | - |
| Revenue | 5.32B | 4.45B | 120% |
| Total Cash | 367M | 201M | 183% |
| Total Debt | 5.12B | 1.11B | 463% |
IDXX | ||
|---|---|---|
OUTLOOK RATING 1..100 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 78 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 16 | |
PRICE GROWTH RATING 1..100 | 57 | |
P/E GROWTH RATING 1..100 | 69 | |
SEASONALITY SCORE 1..100 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| BLCO | IDXX | |
|---|---|---|
| RSI ODDS (%) | 4 days ago 73% | N/A |
| Stochastic ODDS (%) | 4 days ago 84% | 4 days ago 69% |
| Momentum ODDS (%) | 4 days ago 66% | 4 days ago 67% |
| MACD ODDS (%) | 4 days ago 62% | 4 days ago 66% |
| TrendWeek ODDS (%) | 4 days ago 68% | 4 days ago 59% |
| TrendMonth ODDS (%) | 4 days ago 73% | 4 days ago 53% |
| Advances ODDS (%) | 7 days ago 65% | 6 days ago 58% |
| Declines ODDS (%) | 15 days ago 68% | 12 days ago 70% |
| BollingerBands ODDS (%) | 4 days ago 88% | 4 days ago 62% |
| Aroon ODDS (%) | 7 days ago 84% | 4 days ago 70% |
A.I.dvisor indicates that over the last year, BLCO has been loosely correlated with ICUI. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if BLCO jumps, then ICUI could also see price increases.
| Ticker / NAME | Correlation To BLCO | 1D Price Change % | ||
|---|---|---|---|---|
| BLCO | 100% | -0.47% | ||
| ICUI - BLCO | 46% Loosely correlated | +0.08% | ||
| CRL - BLCO | 45% Loosely correlated | -0.90% | ||
| COO - BLCO | 44% Loosely correlated | -0.45% | ||
| MTD - BLCO | 44% Loosely correlated | +2.59% | ||
| RVTY - BLCO | 44% Loosely correlated | -0.90% | ||
More | ||||
A.I.dvisor indicates that over the last year, IDXX has been loosely correlated with ALGN. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if IDXX jumps, then ALGN could also see price increases.
| Ticker / NAME | Correlation To IDXX | 1D Price Change % | ||
|---|---|---|---|---|
| IDXX | 100% | +0.05% | ||
| ALGN - IDXX | 50% Loosely correlated | -2.45% | ||
| SYK - IDXX | 48% Loosely correlated | -6.42% | ||
| BLCO - IDXX | 45% Loosely correlated | -0.47% | ||
| SNN - IDXX | 44% Loosely correlated | -2.38% | ||
| STE - IDXX | 40% Loosely correlated | -1.22% | ||
More | ||||